Skip to main content
OpenTrials

Clinical trial condition

Carcinoma, Bronchogenic

Explore clinical trials studying Carcinoma, Bronchogenic. Study availability and eligibility vary by location and protocol.

5,271 public trials 1,197 recruiting studies
Refine in advanced search Browse all conditions

Carcinoma, Bronchogenic trial results

Active, not recruiting

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

NCT02498613

Conditions
Advanced Malignant Solid Neoplasm, Breast Diseases, Breast Neoplasms, +39 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • UC San Diego Medical Center - Hillcrest San Diego, California, United States
  • UCSF Medical Center-Mount Zion San Francisco, California, United States
View all 16 locations
View Trial Details
Active, not recruiting

A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.

NCT05683977

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +7 more
Locations
  • Research Site Angers, France
  • Research Site Argenteuil, France
  • Research Site Avignon, France
  • Research Site Avignon, France
View all 34 locations
View Trial Details
Active, not recruiting

Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

NCT04140500

Conditions
Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, +32 more
Locations
  • Rigshospitalet København Ø, Denmark
  • Odense Universitetshospital, Onkologisk Afdeling R Odense C, Denmark
  • LLC Arensia Explorer Medicine Tbilisi, Georgia
  • Hadassah University Hospital - Ein Kerem Jerusaelm, Israel
View all 25 locations
View Trial Details
Active, not recruiting

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

NCT04225117

Conditions
Breast Diseases, Breast Neoplasms, Bronchial Neoplasms, +20 more
Locations
  • Arizona Oncology Tucson, Arizona, United States
  • University of California - San Francisco San Francisco, California, United States
  • University of Colorado Aurora, Colorado, United States
  • Florida Cancer Specialists Fort Myers, Florida, United States
View all 39 locations
View Trial Details
Active, not recruiting

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

NCT05358249

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +25 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • NYU School of Medicine New York, United States
  • Novartis Investigative Site Leuven, Belgium
View all 13 locations
View Trial Details
Active, not recruiting

Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations

NCT06245837

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Research Site Arkhangelsk, Russia
  • Research Site Barnaul, Russia
  • Research Site Irkutsk, Russia
  • Research Site Kemerovo, Russia
View all 16 locations
View Trial Details
Active, not recruiting

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

NCT05565378

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • GSK Investigational Site Plantation, Florida, United States
  • GSK Investigational Site Albuquerque, New Mexico, United States
  • GSK Investigational Site Chattanooga, Tennessee, United States
  • GSK Investigational Site Morgantown, West Virginia, United States
View all 99 locations
View Trial Details
Active, not recruiting

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

NCT05801029

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Research Site Hong Kong
  • Research Site Hong Kong
  • Research Site Hong Kong
  • Research Site Shatin, Hong Kong
View all 29 locations
View Trial Details

Related conditions